Differential Antagonism of Human Innate Immune Responses by Tick-Borne Phlebovirus Nonstructural Proteins

Veronica V. Rezelj,a Ping Li,a Vidyanath Chaudhary,b Richard M. Elliott,a† Dong-Yan Jin,b Benjamin Brennana

MRC—University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdoma; School of Biomedical Science, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, Chinab

ABSTRACT In recent years, several newly discovered tick-borne viruses causing a wide spectrum of diseases in humans have been ascribed to the Phlebovirus genus of the Bunyaviridae family. The nonstructural protein (NSs) of bunyaviruses is the main virulence factor and interferon (IFN) antagonist. We studied the molecular mechanisms of IFN antagonism employed by the NSs proteins of human apathogenic Uukuniemi virus (UUKV) and those of Heartland virus (HRTV) and severe fever with thrombocytopenia syndrome virus (SFTSV), both of which cause severe disease. Using reporter assays, we found that UUKV NSs weakly inhibited the activation of the beta interferon (IFN-β) promoter and response elements. UUKV NSs weakly antagonized human IFN-β promoter activation through a novel interaction with mitochondrial antiviral-signaling protein (MAVS), confirmed by coimmunoprecipitation and confocal microscopy studies. HRTV NSs efficiently antagonized both IFN-β promoter activation and type I IFN signaling pathways through interactions with TBK1, preventing its phosphorylation. HRTV NSs exhibited diffused cytoplasmic localization. This is in comparison to the inclusion bodies formed by SFTSV NSs. HRTV NSs also efficiently interacted with STAT2 and impaired IFN-β-induced phosphorylation but did not affect STAT1 or its translocation to the nucleus. Our results suggest that a weak interaction between STAT1 and HRTV or SFTSV NSs may explain their inability to block type II IFN signaling efficiently, thus enabling the activation of proinflammatory responses that lead to severe disease. Our findings offer insights into how pathogenicity may be linked to the capacity of NSs proteins to block the innate immune system and illustrate the plethora of viral immune evasion strategies utilized by emerging phleboviruses.

IMPORTANCE Since 2011, there has been a large expansion in the number of emerging tick-borne viruses that have been assigned to the Phlebovirus genus. Heartland virus (HRTV) and SFTS virus (SFTSV) were found to cause severe disease in humans, unlike other documented tick-borne phleboviruses such as Uukuniemi virus (UUKV). Phleboviruses encode nonstructural proteins (NSs) that enable them to counteract the human innate antiviral defenses. We assessed how these proteins interacted with the innate immune system. We found that UUKV NSs engaged with innate immune factors only weakly, at one early step. However, the viruses that cause more severe disease efficiently disabled the antiviral response by targeting multiple components at several stages across the innate immune induction and signaling pathways. Our results suggest a correlation between the efficiency of the virus protein/host interaction and severity of disease.

KEYWORDS emerging pathogens, nonstructural protein, phlebovirus, bunyavirus, innate immunity

Received 22 May 2017 Accepted 5 June 2017 Published 28 June 2017 Citation Rezelj VV, Li P, Chaudhary V, Elliott RM, Jin D-Y, Brennan B. 2017. Differential antagonism of human innate immune responses by tick-borne Phlebovirus nonstructural proteins. mSphere 2:e00234-17. https://doi.org/10.1128/mSphere.00234-17. Editor John Schoggins, UT Southwestern Medical Center Copyright © 2017 Rezelj et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Address correspondence to Benjamin Brennan, ben.brennan@glasgow.ac.uk. * Present address: Veronica V. Rezelj, Institut Pasteur, Viral Populations and Pathogenesis Unit, Centre National de la Recherche Scientifique UMR 3569, Paris, France. † Deceased 5 June 2015.
Phleboviruses are enveloped, single-stranded RNA viruses belonging to the Bunyamoviridae family. The genus is comprised of over 70 viruses, broadly divided into the sandfly fever group and the Uukuniemi-like group, according to their genomic, antigenic, and vector similarities (1, 2). The viral genome is composed of the large (L), medium (M), and small (S) RNA segments. The L segment encodes the viral RNA-dependent RNA polymerase, the M segment encodes the precursor for the viral glycoproteins (Gn and Gc), and the S segment encodes the nucleocapsid (N) protein and a nonstructural protein (NSs). Viruses belonging to the sandfly fever group are transmitted by dipterans (phlebotomines and mosquitoes) and encode a nonstructural protein (NSm) at the N terminus of their glycoprotein precursor, whereas those within the Uukuniemi-like group are transmitted by ticks and do not encode an NSm protein within their genome (3, 4).

Tick-borne (TiBo) phleboviruses were not considered a public health threat until the emergence of a novel tick-borne Phlebovirus, named severe fever with thrombocytopenia syndrome virus (SFTSV), in China in 2009. The virus caused disease in humans, with a case fatality rate of 12% to 30%, and patients presented with fever, thrombocytopenia, hemorrhagic manifestations, and multiorgan failure (5, 6). SFTSV was later identified in patients exhibiting similar symptoms in Japan and South Korea (7, 8). Shortly after the emergence of SFTSV, a closely related virus, Heartland virus (HRTV), was isolated from patients in Missouri and Tennessee in the United States who presented with fever, fatigue, thrombocytopenia, leukopenia, and, in some cases, multiorgan failure and hemorrhage (9–11). Unlike highly pathogenic TiBo phleboviruses, some viruses, such as the prototype Uukuniemi virus (UUKV), are apathogenic. While antibodies against UUKV-like viruses have been detected in birds, rodents, cows, and humans (12, 13), no disease of medical or veterinary significance has been associated with UUKV infection (14). In recent years, many novel and emerging viruses have been assigned to the Phlebovirus UUKV-like group, including Lone Star virus (LSV) (15), Hunter Island group virus (HIGV) (16), Malsoor virus (MALV) (17), Antigone virus (ANTV) (18), blacklegged tick Phlebovirus (BTPV), and American dog tick Phlebovirus (ADTPV) (19). The continuing expansion of the host and geographical ranges of tick-borne phleboviruses poses a potential risk to both human and animal health.

Following infection of a susceptible host, viruses confront the innate immune system, the first line of defense against viral infections. RNA viruses produce products such as double-stranded RNA (dsRNA) and 5‘-triphosphorylated uncapped single-stranded RNAs (ssRNAs) during replication of their viral genome. These products, or pathogen-associated molecular patterns (PAMPs), are detected by host cell RNA helicases such as those encoded by melanoma differentiation-associated gene 5 (MDA-5) and retinoic acid-inducible gene I (RIG-I), respectively (20). As some negative-strand RNA viruses produce little or undetectable amounts of dsRNA during replication (21, 22), it is hypothesized that these viruses are sensed mainly by RIG-I, through the generation of single-stranded RNA (ssRNA) with uncapped 5’ triphosphate ends (23, 24). Binding of viral RNA to RIG-I results in its activation and the initiation of downstream signaling pathways. Activated RIG-I can recruit the adaptor mitochondrial antiviral signaling protein (MAVS, also known as IPS-1, Cardif, or VISA) through caspase activation and recruitment domains (CARD), which leads to the subsequent activation of interferon (IFN) regulatory factor-3 (IRF-3), IRF-7, and NF-κB via kinases TBK1/IKKε and IKKe/IKKβ, respectively. Activated IRF-3 and NF-κB can then translocate to the nucleus and act as transcription factors for the initiation of interferon (IFN-β) mRNA synthesis (25, 26). Following IFN induction, secreted IFN activates the IFN signaling pathway in neighboring cells by binding to IFN receptors, triggering the activation of the JAK/STAT pathway. Type I IFN signaling results in the formation of the heterotrimer ISGF3, composed of STAT1, STAT2, and IRF-9, which binds to the interferon-stimulated response element (ISRE) and enhances transcription of numerous antiviral interferon-stimulated genes (ISGs) (27).

Bunyaviruses have evolved countermeasures to evade the host innate immune system. The NSs protein is a nonessential protein encoded by some members of the
Bunyaviridae and has been shown to contribute to virus virulence and pathogenesis by acting as an IFN antagonist (28, 29). Within the Phlebovirus genus, studies on the IFN antagonist activity of NSs proteins have focused on mosquito-borne phleboviruses, in particular, that encoded by Rift Valley fever virus (RVFV). With the emergence of highly pathogenic SFTSV, research interests have focused on understanding its underlying molecular mechanisms of pathogenicity. As a result, quickly after its emergence, SFTSV NSs was characterized as a potent antagonist of IFN induction and signaling, through the spatial isolation of TRIM25 and RIG-I (30), TBK1 (31, 32), IRF-3 (31, 32), and STAT1 and STAT2 (33, 34) in NSs-containing, round, cytoplasmic inclusion bodies (IB) or viroplasms. Although the interaction between SFTSV NSs and IKKe or IRF-3 was reported to be indirect, facilitated through the interaction between SFTSV NSs and TBK1 (32), one study also showed a direct interaction of SFTSV NSs with IKKe (31). Similarly, while one study reported a direct interaction between SFTSV NSs and RIG-I (30), no direct interaction was observed in another study (31). We have previously shown that UUKV NSs also acts as an IFN antagonist (35). However, little is known about the mechanism by which UUKV NSs and other tick-borne Phlebovirus NSs proteins impair the innate immune system.

Here we report a study of UUKV and HRTV NSs proteins, focused on understanding their role in antagonizing the human innate immune system at the molecular level, in comparison to the well-characterized SFTSV NSs. We observed that UUKV NSs weakly suppresses IFN induction but not IFN signaling, compared to the potent effects of HRTV and SFTSV NSs in both pathways. Our findings indicate that the weak suppression of IFN induction by UUKV NSs occurs through a direct interaction with MAVS, an early effector protein in the RIG-I signaling pathway. The weak effects of UUKV NSs as an IFN antagonist may provide an explanation for its inability to cause disease in humans, which is in agreement with previous studies (35). For the first time, we show that HRTV NSs acts as a potent antagonist of IFN induction and type I IFN signaling. Moreover, we observed that despite HRTV and SFTSV NSs proteins sharing only 63% amino acid identity (5), some key characteristics of their IFN inhibitory activity are conserved. Our data show that both proteins interact with TBK1 and antagonize its phosphorylation at serine 172 to interfere with IFN induction and with STAT2 to block its phosphorylation and thus interfere with type I IFN signaling. HRTV NSs showed diffused cytoplasmic localization, unlike the inclusion bodies formed by SFTSV NSs to spatially isolate its interacting partners in the IFN induction and signaling pathways. Additionally, we demonstrate that type II IFN signaling is not inhibited by HRTV or SFTSV NSs proteins, presumably due to a weak or indirect interaction of the NSs proteins with STAT1. The inability of HRTV and SFTSV NSs proteins to efficiently block type II IFN signaling might explain the activation of proinflammatory responses that lead to severe disease following virus infection.

The findings presented here expand our knowledge of phleboviral strategies to modulate host innate immune responses and illustrate that TiBo Phlebovirus NSs proteins can evolve divergent mechanisms to antagonize the IFN system.

RESULTS

Diversity of TiBo Phlebovirus NSs subcellular localization. The NSs protein of bunyaviruses is known to exhibit very low conservation at the amino acid level in comparison to other viral proteins (5, 36). Therefore, we speculated that the differences in amino acid sequence could permit the NSs proteins to adopt different IFN antagonism strategies. To begin a basic characterization of tick-borne Phlebovirus NSs proteins, we first compared the amino acid identities of UUKV (GenBank accession no. AAA47959.1), HRTV (GenBank accession no. AFP33392.1), and SFTSV (GenBank accession no. AJD86041.1) NSs proteins using CLUSTAL Omega (37, 38) (Table 1). While UUKV NSs shares low amino acid sequence identity with HRTV (22.73%) and SFTSV (22.22%) NSs, the identity between HRTV and SFTSV NSs proteins is 62.76% (Table 1). Alignments of the amino acid sequences of NSs proteins relevant to this study are shown in Fig. S1 in the supplemental material.
TABLE 1 Percentages of amino acid identity of tick-borne Phlebovirus proteins used in this study

| Virus | Amino acid identity (%) | UUKV | HRTV | SFTSV |
|-------|-------------------------|------|------|-------|
| UUKV  | 100                     | 22.73| 22.22| 22.22 |
| HRTV  | 22.73                   | 100  | 62.67| 62.67 |
| SFTSV | 22.22                   | 62.67| 100  | 100   |

*Values are based on data from GenBank (accession numbers AAA47959.1, AF933392.1, and AJD86041.1 for UUKV, HRTV, and SFTSV NSs, respectively) and were generated using Clustal Omega.

We next compared the subcellular localization of the NSs proteins of UUKV and HRTV to that of SFTSV to give us insights into whether the mechanisms of IFN antagonism between these proteins are divergent or conserved. Human A549 cells were infected at a high multiplicity of infection (MOI) (3 focus-forming units [FFU]/cell) and probed with the respective NSs antibodies 24 h postinfection (p.i.). In agreement with previous reports (39), we observed cytoplasmic distribution of UUKV NSs with small, punctate staining (Fig. 1A). Interestingly, despite the higher percentage of identity between HRTV and SFTSV NSs, we noted that HRTV NSs showed diffused cytoplasmic distribution, whereas SFTSV NSs formed characteristic inclusion bodies (Fig. 1B and C). On the basis of these observations, our findings suggested that UUKV NSs and HRTV NSs may utilize a mechanism different from that of the well-studied SFTSV NSs to circumvent the IFN response.

UUKV, HRTV, and SFTSV NSs proteins, which were tagged at their C terminus with a V5 tag, were used in the rest of this study to enable a comparison of the expression levels of the tagged-NSs proteins in transient-expression assays. Thus, we additionally compared the subcellular localization of the V5-tagged NSs proteins to that of native NSs proteins following virus infection. Expression of V5-tagged UUKV, HRTV, or SFTSV NSs in HEK293T cells revealed that their subcellular localization was like that described for wild-type (wt) protein following virus infection in A549 cells (Fig. 1D).

**Inhibition of IFN induction by TiBo Phlebovirus NSs proteins.** We investigated whether these NSs proteins could inhibit the IFN response at the level of IFN induction. Briefly, HEK293T cells were cotransfected with an inducer plasmid encoding the N-terminal 2CARD domain of RIG-I (pCAGGS-FLAG-2CARD [a kind gift from B. Hale, University of Zurich], here referred to as RIG-I N) and either untagged or V5-tagged UUKV, HRTV, or SFTSV NSs. V5-tagged proteins were used to compare expression levels of proteins in the assays. At 24 h posttransfection (p.t.), IFN production in these cells was quantified using a biological IFN assay. A dose-dependent inhibitory effect of IFN induction was observed for both wt and V5-tagged NSs proteins of all three viruses (Fig. 2A). However, the inhibitory activity of UUKV NSs with respect to IFN induction was distinctly weak compared to that seen with HRTV or SFTSV NSs. At the highest dose (250 ng) of NSs-encoding plasmid, UUKV NSs expression resulted in approximately 60% inhibition of IFN production, whereas that of HRTV and SFTSV NSs was 100% (Fig. 2A). This observation agrees with our recent finding that UUKV NSs acts as a weak IFN antagonist, shown by the creation of a recombinant UUKV lacking NSs (35). HRTV and SFTSV NSs proteins strongly antagonized the production of IFN (Fig. 2A). A difference in the levels of efficiency with which HRTV and SFTSV NSs can block IFN production was observed. While an approximately 50% decrease in relative IFN production was observed at the lowest dose of HRTV NSs (10 ng), this dose of SFTSV NSs resulted in an almost 95% decrease in IFN production (Fig. 2A). However, examination of the cell lysates by Western blotting revealed V5-tagged HRTV NSs expression levels that were visibly lower than those seen with SFTSV and UUKV NSs proteins (Fig. 2B). In fact, transfection of 50 ng of V5-tagged HRTV NSs resulted in expression levels similar to those seen with 10 ng of V5-tagged SFTSV NSs (Fig. 2B), and the same level of inhibition of IFN production was observed with these respective amounts (Fig. 2A). Regardless, these results indicated that all NSs proteins examined were capable of inhibiting the induction of IFN.
The transcription factor interferon regulatory factor 3 (IRF-3) is ubiquitously expressed in cells. Following activation of the IFN pathway, IRF-3 is phosphorylated by TANK-binding kinase-1 (TBK1), which allows its homodimerization prior to translocation to the nucleus (40–43). Thus, we investigated whether the NSs proteins inhibited the induction of IFN by ultimately preventing the activation of IRF-3. HEK293T cells were induced with a RIG-I N-encoding plasmid in the presence of 250 ng of untagged or V5-tagged NSs proteins and were subsequently harvested for analysis of IRF-3 phosphorylation. IRF-3 phosphorylated at Ser386 could be readily detected in the mock cells stimulated with RIG-I N and also in the presence of UUKV NSs (Fig. 2C). Under all experimental conditions, the levels of total IRF-3 remained unchanged. Similarly, when cell lysates were analyzed under nondenaturing conditions,
the dimeric form of IRF-3 could be detected only in the presence of UUKV NSs but not HRTV or SFTSV NSs. A shift in molecular weight was observed for the V5-tagged UUKV NSs under nonreducing conditions (Fig. 2D).

Taken together, these data indicate that, in contrast to UUKV NSs, HRTV and SFTSV NSs proteins can efficiently antagonize IFN induction, ultimately hindering the activation of IRF-3 and thus blocking activation of the IFN-$\beta$ promoter. On the other hand, UUKV NSs, a weak IFN antagonist, is unable to completely inhibit the activation of IRF-3 and the subsequent production of IFN.

**UUKV NSs exerts its IFN-antagonistic activity at the level of MAVS, while HRTV NSs antagonizes at the level of TBK1.** To elucidate the stage of the IFN induction pathway at which UUKV and HRTV NSs proteins antagonize this response, we performed an IFN-$\beta$ reporter assay in the presence of UUKV or HRTV NSs, using SFTSV NSs as a control. Various effectors of the IFN induction pathway (constitutively active RIG-I...
overexpressed in HEK293T cells to examine the activation of the IFN-β promoter in the presence of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs. For UUKV NSs, inhibition was observed only in the MAVS induction reporter assay (Fig. 3B) and not in the RIG-I N, TBK1, IKKβ, or IRF-3 5D induction assays (Fig. 3A and C to E). As RIG-I is involved in the activation of MAVS, the lack of inhibition by UUKV NSs at the level of RIG-I (Fig. 3A) despite its inhibition of MAVS-induced IFN-β promoter activation (Fig. 3B) was surprising. It is possible that the overexpression of RIG-I N allows the detection of an inhibitory effect of UUKV NSs on IFN production in a biological IFN assay (Fig. 3A) whereas measurement of luciferase activity upon the transactivation of the murine

**FIG 3** UUKV NSs protein inhibits IFN-β induction at the level of MAVS, whereas HRTV NSs antagonizes at the level of TBK1. (A to E) HEK293T cells were cotransfected with a Firefly luciferase reporter plasmid under the control of an IFN-β promoter and a Renilla luciferase control plasmid in the presence of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins. The cells were stimulated by cotransfection of inducer plasmids encoding FLAG-tagged RIG-I N (A), MAVS (B), TBK1 (C), or IκB kinase ε (IKKe) (D) or by cotransfection of a plasmid expressing untagged IRF3-5D (E). Fold induction was obtained by normalizing the luciferase values to the nonstimulated mock control sample values. Western blots of transfected cell lysates are shown in the lower panels. The data represent results of three independent experiments performed in duplicate (n = 3), presented as fold induction means ± SD. Statistical significance for the comparison of means between groups was determined by one-way ANOVA followed by Dunnett’s multiple-comparison post hoc tests. ****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05.

[RIG-I N], MAVS, TBK1, IKKe, or a phosphomimetic, active form of IRF-3 (IRF-3 5D)] were overexpressed in HEK293T cells to examine the activation of the IFN-β promoter in the presence of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs. For UUKV NSs, inhibition was observed only in the MAVS induction reporter assay (Fig. 3B) and not in the RIG-I N, TBK1, IKKe, or IRF-3 5D induction assays (Fig. 3A and C to E). As RIG-I is involved in the activation of MAVS, the lack of inhibition by UUKV NSs at the level of RIG-I (Fig. 3A) despite its inhibition of MAVS-induced IFN-β promoter activation (Fig. 3B) was surprising. It is possible that the overexpression of RIG-I N allows the detection of an inhibitory effect of UUKV NSs on IFN production in a biological IFN assay (Fig. 3A) whereas measurement of luciferase activity upon the transactivation of the murine
IFN-β promoter saturates the weak inhibitory effect of UUKV NSs at the level of RIG-I N (Fig. 3A). A small increase in IFN production was detected upon transfection of RIG-I N and UUKV NSs or NSs-V5; however, this increase was not significant and was within the limits of experimental variation within the system.

Transactivation of the IFN-β promoter was inhibited by HRTV NSs and SFTSV NSs upon stimulation by RIG-I N, MAVS, and TBK1 (Fig. 3A to C) but not by downstream factors IKKe and IRF-3 5D (Fig. 3D and E). While 99.7% inhibition of TBK1-induced activation of the IFN-β promoter by untagged and V5-tagged SFTSV NSs was observed, only 43% inhibition by untagged and V5-tagged HRTV NSs was observed (Fig. 3C). Of note, the difference in the levels of efficiency of antagonism of TBK1-induced IFN-β promoter activation may be explained by the fact that the levels of HRTV NSs expression were lower than the levels of SFTSV NSs expression, as detected by Western blotting of transfected cell lysates (Fig. 3C). Our data suggest that UUKV NSs inhibits IFN production at the level of MAVS, whereas HRTV NSs inhibits RIG-I N, MAVS-, and TBK1-induced IFN-β reporter activity.

**UUKV NSs antagonizes IFN induction through a direct interaction with MAVS.**

We investigated whether the ability of UUKV NSs to inhibit IFN induction was due to a direct interaction with effectors of the IFN induction pathway. HEK293T cells were cotransfected with V5-tagged UUKV NSs and each of the FLAG-tagged IFN induction components or untagged IRF-3 5D, and the cell lysates were subjected to coimmunoprecipitation (co-IP) using anti-FLAG or anti-IRF-3 antibodies 18 h posttransfection. UUKV NSs was coimmunoprecipitated only with FLAG-tagged RIG-I N and MAVS and not with TBK1, IKKe, or IRF-3 5D (Fig. 4A). As a control, we confirmed that no V5-tagged NSs was pulled down from transfected cells during co-IP using anti-FLAG beads or anti-IRF-3 antibody (Fig. S2). RIG-I can interact with MAVS through its N-terminal 2CARD domain (44, 45). Thus, to ensure that the pulldown of UUKV NSs with RIG-I N or MAVS was not due to indirect interactions, we carried out reverse co-IPs. HEK293T cells transiently expressing V5-tagged UUKV NSs and FLAG-tagged RIG-I N or MAVS were subjected to co-IP with an anti-V5 antibody. Under these conditions, FLAG-tagged MAVS, but not FLAG-tagged RIG-I N, could be coimmunoprecipitated in the presence of V5-tagged UUKV NSs (Fig. 4B). These results were also confirmed in the context of UUKV infection. HEK293T cells were infected with UUKV at a high MOI (20 FFU/cell) for 8 h, followed by transient expression of FLAG-tagged RIG-I N or MAVS. At 30 h p.i., cell lysates were subjected to immunoprecipitation using an anti-UUKV NSs antibody. While no RIG-I N was coimmunoprecipitated with UUKV NSs (Fig. 4C, left panel), a weak band was observed for MAVS (Fig. 4C, right panel). The detection of a weak signal for MAVS (detectable only upon long exposure of the membrane), relative to the expression levels detected in the whole-cell lysate, suggested a weak interaction between UUKV NSs and MAVS.

Next, we examined whether UUKV NSs and MAVS could colocalize to confirm our co-IP and reporter assay data. We overexpressed FLAG-tagged MAVS together with V5-tagged UUKV NSs in HEK293T cells. Following its activation, MAVS has been reported to adopt a speckled staining pattern (46). Expression of V5-tagged UUKV NSs exhibited the characteristic punctate, cytoplasmic staining described above (Fig. 1A and D). We found that overexpression of FLAG-tagged MAVS in HEK293T cells resulted in the distinct speckled staining characteristic of the active form of MAVS (Fig. 4D). Although colocalization of UUKV NSs and MAVS was not obvious in some cells, close examination revealed partial colocalization of the UUKV NSs punctate staining with MAVS speckles (Fig. 4D). Partial colocalization of UUKV NSs with MAVS agrees with our proposed hypothesis that the interaction between MAVS and UUKV NSs is weak, which could explain its weak IFN-antagonistic activity.

**HRTV NSs antagonizes IFN induction through a direct interaction with TBK1.**

To elucidate the interacting partners of HRTV NSs, we took an approach similar to the one taken for UUKV NSs. Cotransfection of V5-tagged HRTV NSs and each of the FLAG-tagged IFN induction components resulted in the co-IP of HRTV NSs in the presence of TBK1 only (Fig. 5A). Similar results were observed for SFTSV NSs, as previously reported.
UUKV NSs interacts with MAVS. (A) HEK293T cells were cotransfected with a V5-tagged UUKV NSs-encoding plasmid along with FLAG-tagged RIG-I (N) MAVS, TBK1, IKKε, or untagged IRF3-5D-encoding plasmids. Transfected cell lysates were subjected to coimmunoprecipitation (co-IP) with beads conjugated to FLAG or IRF3 antibodies. V5-tagged UUKV NSs was detected through Western blotting with an anti-V5 antibody. (B) Reverse co-IP. HEK293T cells were mock transfected or transfected with V5-tagged UUKV NSs and FLAG-tagged RIG-I N (left panel) or MAVS (right panel). Cell lysates were subjected to co-IP with an (Continued on next page)
TBK1 activation is achieved through phosphorylation of Ser172 (pTBK1) within its classical kinase activation loop by the action of IKKβ. Furthermore, TBK1 can also autophosphorylate at Ser172, leading to its activation when overexpressed in HEK293T cells (47–50). Thus, we investigated whether HRTV or SFTSV NSs could prevent the activation of TBK1 by inhibiting its phosphorylation at Ser172, thereby blocking IFN induction. HEK293T cells were induced by a plasmid encoding FLAG-tagged TBK1 in the presence of 250 ng of untagged or V5-tagged NSs proteins and were subsequently harvested for analysis of TBK1 phosphorylation. TBK1 phosphorylated at Ser172 could be readily detected in the mock cells stimulated with TBK1 (Fig. 5C). Reduced levels of phosphorylated TBK1 were observed in the presence of HRTV or SFTSV NSs. However, the block in phosphorylation appeared to be greater in the presence of SFTSV NSs than in the presence of HRTV NSs whereas the levels of total TBK1 remained unchanged under all experimental conditions. Of note, the difference in the levels of efficiency of antagonism of TBK1 phosphorylation could once again be explained by the levels of HRTV NSs expression being lower than those of SFTSV NSs expression, as detected by Western blotting of transfected cell lysates (Fig. 5C).

We examined the subcellular localization of TBK1 in the presence or absence of HRTV or SFTSV NSs in HEK293T cells. On its own, TBK1 showed cytoplasmic staining (Fig. 5D). There was a clear sequestration of TBK1 to the inclusion bodies in SFTSV NSs-transfected cells, as previously described by several groups. However, in cells transiently expressing HRTV NSs, TBK1 remained cytoplasmic but colocalized with the HRTV NSs signal (Fig. 5D). Interestingly, despite exhibiting very different cellular localization, the strategy by which the antagonistic function of HRTV NSs occurs appears to mirror that of SFTSV, i.e., blocking the phosphorylation and hence activation of TBK1. Thus, our findings suggest that HRTV NSs and SFTSV NSs share some key characteristics: IFN antagonist activity and interaction with TBK1.

HRTV and SFTSV, but not UUKV NSs, impair type I IFN signaling through an interaction with STAT2 but do not inhibit type II IFN signaling. To assess whether UUKV and HRTV NSs could inhibit type I IFN signaling, we transfected HEK293T cells with a reporter plasmid encoding luciferase under the control of an interferon-stimulated response element (ISRE) promoter along with constructs expressing the viral NSs proteins, using SFTSV NSs as a control, as SFTSV NSs has been shown to act as a potent antagonist of IFN signaling (30–34). Interestingly, UUKV NSs was unable to abrogate type I IFN signaling. In comparison, HRTV NSs and SFTSV NSs exhibited a strong inhibitory effect on ISRE promoter activation (Fig. 6A). As already noted, expression of HRTV NSs was lower than that of UUKV NSs or SFTSV NSs in these assays, which was demonstrated by Western blotting of the cell lysates transfected with V5-tagged NSs proteins (Fig. 6B).

Other published data show that SFTSV NSs directly interacts with and sequesters STAT1 and STAT2 into inclusion bodies to block type I IFN signaling (33, 34). To investigate whether HRTV NSs was also capable of these interactions, we performed immunoprecipitation of transfected V5-tagged NSs proteins (Fig. 6C). In agreement with our reporter assay, no interaction between UUKV NSs and STAT1 or STAT2 was observed with the anti-V5 antibody. FLAG-tagged RIG-I N and MAVS in the co-IP eluates were detected by Western blotting with an anti-FLAG antibody. (C) co-IP of UUKV NSs upon UUKV infection in the presence of FLAG-tagged RIG-I N or MAVS. HEK293T cells were mock infected or infected with UUKV at a high MOI (20 FFU/cell) for 8 h, followed by mock transfection or transfection of FLAG-tagged RIG-I N-encoding plasmids (left panel) or MAVS-encoding plasmids (right panel). At 30 h p.i., the cell lysates were subjected to co-IP using an anti-UUKV NSs antibody, followed by detection of FLAG-tagged RIG-I N or MAVS and UUKV NSs by Western blotting. (D) Subcellular localization of UUKV NSs-V5 and FLAG-tagged MAVS. HEK293T cells were mock transfected or transfected with UUKV NSs-V5 or FLAG-tagged MAVS or both. At 24 h posttransfection, the cells were fixed, permeabilized, and probed with V5 (red) and FLAG (green) antibodies. DAPI-stained nuclei (blue) and subcellular localization of the proteins were analyzed by confocal microscopy. Intensity profile graphs are shown at the bottom of the image (x axis, distance [in micrometers]; y axis, intensity). Scale bars indicate 10 μm. IP, immunoprecipitation; WB, Western blotting; WCL, whole-cell lysate.
observed. Like SFTSV NSs, endogenous STAT1 and STAT2 were coimmunoprecipitated with HRTV NSs, suggesting that the IFN signaling interacting partners of these two proteins are conserved (Fig. 6C). Interestingly, STAT2 levels in IP eluates were higher than those of STAT1 (relative to the respective total expression levels in the whole-cell lysate). Indeed, a longer exposure was required to detect STAT1 in immunoprecipitated samples, suggesting that the interaction of HRTV NSs or SFTSV NSs with STAT2 is

**FIG 5** HRTV NSs interacts with TBK1. (A) HEK293T cells were cotransfected with a V5-tagged HRTV NSs-encoding plasmid along with FLAG-tagged RIG-I (N), MAVS, TBK1, or IκB or untagged IRF3-5D-encoding plasmids. Transfected lysates were subjected to coimmunoprecipitation with beads conjugated to FLAG or IRF3 antibodies. V5-tagged HRTV NSs was detected through Western blotting with an anti-V5 antibody. (B) Immunoprecipitation of HRTV NSs in infected cells. Cell lysates of A549 cells infected with HRTV (MOI 10 FFU/cell) were subjected to immunoprecipitation with an anti-HRTV NSs antibody. Western blotting was performed on IP eluates to detect the presence of TBK1 and HRTV NSs in HRTV-infected cells. (C) HEK293T cells were cotransfected with plasmids expressing untagged or V5-tagged HRTV or SFTSV NSs and FLAG-tagged TBK1 to induce interferon induction. At 24 h posttransfection, cell lysates were harvested and utilized for Western blotting of TBK1, TBK1 phosphorylated at Ser172, tubulin, and V5 with the appropriate antibodies. WB, Western blot. (D) Indirect immunofluorescent staining of HEK293T cells transiently expressing TBK1-FLAG and V5-tagged HRTV or SFTSV NSs and probed with anti-TBK1 and anti-V5 antibodies 24 h posttransfection. Subcellular localization of NSs proteins (red), TBK1 (green), and nuclei stained with DAPI (blue) was analyzed by confocal microscopy. Intensity profile graphs are shown to the right of the image. Scale bars indicate 20 μm.
stronger than that with STAT1. It is also possible that STAT1-STAT2 heterodimers are precipitated in the presence of HRTV and SFTSV NSs proteins and therefore that the precipitated STAT1 is not a result of a direct interaction with the NSs proteins but is rather a result of an indirect interaction through STAT2.

STAT3 is a pleiotropic STAT that has been implicated in modulating inflammatory responses in type I IFN signaling (51) as well as in regulating T cell proliferation by preventing apoptosis (52) and CD4+ and CD8+ T cell survival and differentiation (53, 54). With this in mind, we also investigated whether the NSs proteins of tick-borne phleboviruses would interact with STAT3. No STAT3 was pulled down following immunoprecipitation of V5-tagged proteins (Fig. 6D).

The ultimate translocation of STAT1 and STAT2 proteins to the nucleus to activate the promoter of ISGs occurs via their phosphorylation and dimerization (55, 56). While one study has shown that only STAT2 (but not STAT1) phosphorylation is inhibited by SFTSV NSs (34), another study has shown that the phosphorylation of STAT2 as well as of STAT1 at position Ser727 is blocked by SFTSV NSs (33). We examined the ability of HRTV or SFTSV NSs to inhibit STAT1 or STAT2 phosphorylation using UUKV NSs as a negative control, as UUKV NSs did not block type I IFN signaling (Fig. 6A). HEK293T cells transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins were treated with recombinant IFN-β for 30 min, and the cell lysates were harvested for Western blotting 24 h posttransfection. Unlike Chaudhary et al. (33), we observed no difference in the levels of STAT1 or phosphorylated STAT1 (at position Ser727 or position Tyr701) in the presence of SFTSV NSs compared to the mock control. Similar results were observed for UUKV and HRTV NSs proteins (Fig. 6E). While in the presence of the tick-borne Phlebovirus NSs proteins STAT2 levels also remained unchanged compared to those seen with the mock control, we observed a reduction in the levels of STAT2 phosphorylation (position Tyr690) in the presence of HRTV and SFTSV NSs proteins compared to the levels found in the mock control and the UUKV NSs-transfected controls (Fig. 6E).

We next sought to compare the effect of HRTV NSs on the translocation of STAT1 and STAT2 to the nucleus upon IFN stimulation to that of SFTSV NSs. To do this, we used HeLa cells, which have been utilized previously to visualize the sequestration of STAT1 and STAT2 into SFTSV NSs-formed inclusion bodies (33). HeLa cells transiently expressing V5-tagged HRTV or SFTSV NSs were treated with IFN-β for 30 min at 24 h p.t. prior to analysis with V5 and STAT1 or STAT2 antibodies. Although STAT1 was sequestered into the characteristic inclusion bodies in cells transiently expressing SFTSV NSs, its translocation to the nucleus due to IFN-β stimulation was not completely inhibited, as nuclear STAT1 could also be detected (Fig. 6F). Expression of HRTV NSs did not result in an accumulation of STAT1 into inclusion bodies as noted for SFTSV; instead, STAT1 appeared diffused throughout the cytoplasm, as well as in the nucleus (Fig. 6F). In contrast to what was observed with STAT1, no nuclear translocation of STAT2 was detected in cells transiently expressing V5-tagged HRTV or SFTSV NSs upon IFN treatment (Fig. 6G). As with TBK1, STAT2 remained diffused in the cytoplasm in the

FIG 6  HRTV and SFTSV NSs, but not UUKV NSs, inhibits JAK/STAT IFN signaling. (A) ISRE reporter assay in the presence of tick-borne Phlebovirus NSs proteins. HEK293T cells were transfected with a Firefly luciferase reporter plasmid under the control of an ISRE promoter and a Renilla luciferase control plasmid in the presence of the indicated amounts of untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins. The cells were stimulated with IFN-β (500 U/ml) 24 h posttransfection and lysed 18 h later for analysis. Induction was normalized against the induction control, whose results were assigned a value of 100%. The data represent results of three independent experiments performed in duplicate (n = 3), presented as fold induction means ± SEM. RLU, relative light units. (B) Western blots of transfected cell lysates. (C and D) Cell lysates from HEK293T cells transiently expressing V5-tagged UUKV, HRTV, or SFTSV NSs were immunoprecipitated with an anti-V5 antibody and analyzed by Western blotting with STAT1 and STAT2 antibodies (C) or with a STAT3 antibody (D). (E) Phosphorylation of STAT1 and STAT2 in HEK293T cells upon treatment with recombinant IFN-β. HEK293T cells transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV NSs were treated with recombinant IFN-β 24 h posttransfection. Upon 30 min of IFN-β treatment, the cell lysates were harvested and utilized for Western blotting of STAT2, STAT2 phosphorylated at Tyr690, STAT1, STAT1 phosphorylated at Ser727 or Tyr701, actin, and V5 with the appropriate antibodies. (F and G) HeLa cells were transfected with plasmids encoding V5-tagged HRTV or SFTSV NSs. At 24 h posttransfection, the cells were treated with IFN-β (1,000 U/ml) for 30 min, fixed, permeabilized, and probed with (V) STAT1 (F) and STAT2 (G) antibodies to visualize the subcellular localization of endogenous STATs (red), V5-tagged NSs (green), and DAPI-stained nuclei (blue) by confocal microscopy. Scale bars indicate 20 μm. (H) HEK293T cells transiently expressing untagged or V5-tagged UUKV, HRTV, or SFTSV NSs proteins were treated with 50 ng IFN-γ. At 24 h posttreatment, total cellular RNA was isolated and subjected to RT-qPCR to examine mRNA levels of IP-10 and CXCL10. Fold increase was derived by normalizing relative mRNA levels of the target to GAPDH mRNA levels using a ΔΔCT method.
presence of HRTV NSs, in comparison to a clear sequestration into the inclusion bodies formed by SFTSV NSs. Thus, these results indicate that the interaction of HRTV NSs or SFTSV NSs protein with STAT2 (but not STAT1) results in the efficient inhibition of IFN-β-induced STAT2 nuclear translocation. Perhaps the leakage of STAT1 into the nucleus in the presence of HRTV NSs or SFTSV NSs following IFN-β treatment is a result of a weak (or indirect) interaction between the NSs proteins and STAT1, as noted from our co-IP experiments.

As type II IFN signaling is mediated by STAT1 homodimers, we investigated whether the weak or indirect interaction of HRTV and SFTSV NSs with STAT1 could result in an inhibitory effect upon type II IFN signaling. mRNA levels of two IFN-γ-induced ISGs (IRF-1 and CXCL10) were investigated following IFN-γ treatment of HEK293T cells transiently expressing HRTV or SFTSV NSs proteins, using UUKV NSs as a control (Fig. 6H). No effect was observed on mRNA levels of IRF-1 and CXCL10 in cells transiently expressing UUKV, HRTV, or SFTSV NSs proteins following IFN-γ treatment. This finding suggests that the interaction of HRTV and SFTSV NSs with STAT1 does not inhibit type II IFN signaling.

To summarize, our results indicate that impairment of type I IFN signaling by HRTV and SFTSV NSs occurs mainly in a STAT2-dependent manner, whereas no impairment of IFN signaling by UUKV NSs was detected. Additionally, only the phosphorylation and nuclear translocation of STAT2 are efficiently impaired by HRTV and SFTSV NSs proteins upon IFN-β treatment. These observations suggest that both HRTV and SFTSV NSs proteins have a conserved direct interaction with STAT2 which enables the proteins to efficiently antagonize type I IFN signaling (Fig. 6A). On the other hand, their weak or indirect interaction with STAT1 does not enable HRTV and SFTSV NSs proteins to inhibit type II IFN signaling (Fig. 6H).

Comparison of the levels of TiBo Phlebovirus sensitivity to the interferon response. Different strains of mosquito-borne Rift Valley fever virus (RVFV) exhibit differential sensitivities to the action of IFN depending on the capacity of the NSs proteins of the various strains to efficiently block the type I IFN response (57). To investigate the sensitivity of tick-borne phleboviruses to virus-induced IFN, we examined the effect of a JAK1/2 inhibitor, ruxolitinib (previously described in reference 58), on focus formation. While UUKV foci were undetectable in A549 cells, treatment with ruxolitinib restored the ability of UUKV to form foci in these cells (Fig. 7A). In contrast, ruxolitinib treatment had no significant effect on HRTV focus size. Unexpectedly, and even though the SFTSV genome encodes an NSs protein that is a potent inhibitor of the IFN system (30–34), we observed a significant increase in SFTSV focus size in A549 cells treated with ruxolitinib (Fig. 7A). Thus, despite encoding a potent IFN antagonist, SFTSV infection still results in IFN induction (Fig. 7G), thereby limiting virus infection in neighboring cells. To ensure that this effect was not due to the presence of defective interfering particles in our SFTSV stock, the virus was subjected to plaque purification. Four different newly plaque-purified SFTSV stocks yielded results similar to those obtained with our laboratory SFTSV stock (data not shown).

To corroborate the results obtained with ruxolitinib treatment, the growth kinetics of UUKV, HRTV, and SFTSV were compared at a low MOI and a high MOI (0.1 FFU/cell and 3 FFU/cell, respectively) in A549 cells. At the indicated time points, cell culture supernatants were harvested, virus titers were determined, and the relative amounts of IFN produced were quantified through biological IFN assays. The findings presented in Fig. 7B to G support the results obtained by measuring IFN sensitivity using ruxolitinib treatment. At the low MOI, infection with UUKV and SFTSV resulted in mean peak titers of $2 \times 10^4$ FFU/ml and $8.2 \times 10^5$ FFU/ml at 72 h p.i., respectively, approximately 1-log lower than the titers seen when cells were infected at the high MOI (Fig. 7B and D). While UUKV infection induced IFN by 24 h p.i. following the high-MOI infection, no IFN could be detected at the low MOI (Fig. 7E). The lack of IFN production by UUKV at the low MOI could be explained by the low replication levels seen throughout the time course, as only a 1-log increase in virus titer was observed by 72 h p.i. On the other hand, faster growth kinetics exhibited by SFTSV (a 3-log increase in virus titer) resulted
in increased induction of IFN by SFTSV at the low MOI (Fig. 7G). In contrast to UUKV and SFTSV, the high and low MOI growth curves of HRTV showed similar mean titers by 72 h p.i. (at the low MOI, $1.7 \times 10^5$ FFU/ml; at the high MOI, $3.3 \times 10^5$ FFU/ml) (Fig. 7D). Furthermore, even at the high MOI, HRTV infection resulted in very little induction of IFN (4 relative IFN units [RIU]) by 72 h p.i. (Fig. 7F). Though surprising, our data showing the induction of IFN by SFTSV despite its being equipped with a potent antagonist of the IFN system agree with a recent study. That study demonstrated that sera from SFTSV-infected patients showed high concentrations of IFN-α compared to sera from healthy patients and that the concentration of IFN-α in patients with severe SFTSV was significantly higher than that in patients with mild SFTS (59).

Taken together, these data demonstrate that UUKV and SFTSV cannot efficiently antagonize IFN production during infection and that induction of IFN leads to reduced spread of the virus to neighboring cells. On the other hand, we show that HRTV can limit IFN production following infection.

**FIG 7** Sensitivity of tick-borne phleboviruses to IFN. (A) Focus-forming assays of UUKV, HRTV, and SFTSV on A549 cells 6 days p.i. The overlay was supplemented with JAK/STAT inhibitor ruxolitinib (0.4 μM) or the equivalent volume of the vehicle control DMSO. Foci were detected using anti-UUKV, HRTV, or SFTSV N antibodies. (B to D) Growth curves of UUKV (B), HRTV (C), or SFTSV (D) at a low MOI (0.1 FFU/cell) and a high MOI (3 FFU/cell) in A549 cells. The cell culture supernatant of triplicate wells was collected at the indicated time points, and virus titers were determined through focus-forming assays. *, $P \leq 0.05$. (E to G) Samples from the experiments described for panels B to D were subjected to UV inactivation, and the relative IFN units were quantified through a biological IFN assay. Error bars indicate SD of the means. The results shown in this figure are representative of 2 experimental repeats.
DISCUSSION

Phleboviruses have a trisegmented negative or ambisense RNA genome that can activate IFN induction by the stimulation of RIG-I. Induction of type I IFN at an early stage following virus infection can have protective effects against virus infection, which is best illustrated by the high susceptibility of type I IFN receptor knockout mice to virus infection compared to wild-type mice (57, 60, 61). Consequently, phleboviruses require efficient mechanisms to antagonize the IFN response. Recent reviews have highlighted the importance of elucidating the countermeasures employed by phleboviruses to hinder the IFN response (62, 63). These recommendations come with the realization that, until the recent emergence of highly pathogenic SFTSV, most studies focused on the ability of the NSs protein of mosquito-borne phleboviruses, in particular, RVFV NSs protein, to overcome the IFN system. However, unlike most other Phlebovirus NSs proteins, RVFV NSs localizes to the nucleus, forming unique filamentous structures in the nuclei of infected cells (64–68). Part of the IFN-antagonistic activity of RVFV NSs is attributed to its nuclear localization, which allows it to suppress host cell transcription generally but also IFN-β mRNA synthesis specifically (69–71). RVFV NSs has also been implicated in preventing the inhibition of translation by the proteasome-dependent downregulation of double-stranded RNA-dependent protein kinase (PKR) (72–76). Like RVFV, the NSs protein of mosquito-borne Toscana virus (TOSV) can induce proteasome-mediated degradation of PKR (77), but it can additionally inhibit the production of IFN through a direct interaction with RIG-I (78, 79). The NSs protein of Punta Toro virus (PTV; also mosquito-borne) acts as a suppressor of the IFN response by inhibiting host cell transcription like RVFV NSs but does not affect PKR levels (77, 80).

With the emergence of SFTSV in China and the discovery of HRTV in the United States, there is now a pressing need to understand the molecular mechanisms of virulence of these pathogens and those of other previously described and neglected tick-borne phleboviruses. The discovery that SFTSV NSs forms unique cytoplasmic inclusion bodies which act to sequester elements from the IFN induction and IFN signaling pathways suggested that Phlebovirus NSs proteins have evolved highly divergent mechanisms to counteract the human IFN response (30–34, 81). This is underscored by the fact that within the Phlebovirus genus, the NSs protein sequence has extremely low conservation at the amino acid level in comparison to the other viral proteins (5).

In this report, we highlight the diverse mechanisms that tick-borne Phlebovirus NSs proteins employ to antagonize the IFN response, by demonstrating that UUKV NSs and HRTV NSs utilize strategies different from those employed by the well-studied SFTSV NSs to subvert this powerful antiviral response. The proposed model of tick-borne Phlebovirus NSs antagonism of the IFN response is summarized in Fig. 8. Our reporter assays showed that the NSs protein of apathogenic UUKV acts as a weak antagonist of IFN induction, but not of IFN signaling, which agrees with our previous studies (35) (Fig. 2 and 6). This is in comparison to the strong inhibition of IFN-β and ISRE promoter activation seen with the NSs proteins belonging to the more pathogenic HRTV and SFTSV. As UUKV has been associated with infection in birds (14, 82, 83), it would be of interest to investigate in future studies whether its NSs protein has adapted to antagonize the avian innate immune system with higher efficiency than was seen with the human innate immune system tested here. Our reporter assays and coimmunoprecipitation studies further demonstrated that the molecular mechanism regulating the inhibition of IFN induction by UUKV NSs likely operates through a direct interaction with MAVS, an effector protein involved in the early stages of the IFN induction pathway (Fig. 3 and 4). Examination of this interaction through confocal microscopy studies revealed that some punctate cytoplasmic structures of UUKV NSs colocalize with speckle-like structures formed by MAVS (Fig. 4D), which may inhibit MAVS activation and downstream signaling of IFN induction. Toscana virus (TOSV) NSs protein has also been shown to inhibit the induction of type I IFN at early stages of the IFN induction pathway by targeting RIG-I for proteasomal degradation (78). The influenza
A virus PB1-F2 protein has also been shown to suppress IFN induction by binding to MAVS and altering the mitochondrial membrane potential (84, 85), which is required for MAVS-mediated IFN induction (86). Studies are in progress to understand whether UUKV NSs utilizes mechanisms to suppress IFN induction that are similar to those described for influenza virus PB1-F2 protein. As it stands, and to our knowledge, targeting MAVS to antagonize the type I IFN response is a novel strategy described for Phlebovirus NSs proteins.

Our results show, for the first time, that HRTV NSs acts as a potent antagonist of both IFN induction and type I IFN signaling (Fig. 2 and 6). Reporter assays and co-IP experiments enabled us to determine that the ability of HRTV NSs to block IFN induction and type I IFN signaling is facilitated through a direct interaction with TBK1 and STAT2, respectively (Fig. 5 and 6). Despite HRTV NSs sharing only 63% amino acid...
identity with SFTSV NSs, the interactions reported here are conserved with those of SFTSV NSs, which also interacts with TBK1 and STAT2, antagonizing their phosphorylation to inhibit the IFN response (30, 31, 34). However, while SFTSV NSs spatially isolates TBK1 and STAT2 into inclusion bodies, the interactions between HRTV NSs and TBK1 and STAT2 were notably different in terms of subcellular localization, as these proteins remained diffused in the cytoplasm in the presence of HRTV NSs (Fig. 5 and 6). It was previously reported that the N-terminal PxxP motif (amino acid residues 66 to 69) of SFTSV NSs is required for the formation of inclusion bodies (31). Simultaneous substitution of Pro66 and Pro69 resulted in diffused cytoplasmic localization and affected the IFN-antagonistic activity of SFTSV NSs. Surprisingly, the PxxP motif was conserved in HRTV NSs (see Fig. S1 in the supplemental material), indicating that the motif may be required but is not sufficient for inclusion body formation and the IFN antagonistic activity of NSs. Nonetheless, a direct interaction of HRTV NSs with TBK1 in the cytoplasm, rather than sequestration to inclusion bodies, was sufficient to prevent its activation by blocking TBK1 phosphorylation of Ser172 and the subsequent phosphorylation of downstream factors.

In terms of IFN signaling, our co-IP assays demonstrated that HRTV and SFTSV NSs could interact with both STAT1 and STAT2 (Fig. 6C). However, a stronger interaction was observed with STAT2 than with STAT1. Additionally, IFN-β-induced phosphorylation and nuclear translocation of STAT2, but not STAT1, were efficiently inhibited in the presence of HRTV or SFTSV NSs proteins (Fig. 6E to G).

In a manner similar to its interaction with TBK1, the mechanism by which SFTSV NSs inhibits STAT1 and STAT2 translocation to the nucleus operates through their spatial isolation in inclusion bodies (34). No spatial isolation of STAT1 or STAT2 was observed in the presence of HRTV NSs, suggesting simply that an interaction between HRTV NSs and STAT2 may block phosphorylation of STAT2 and its heterodimerization with STAT1, consequently inhibiting the translocation of STAT1-2 heterodimers to the nucleus and thus inhibiting type I and type III IFN signaling. It remains to be elucidated whether the coimmunoprecipitation of STAT1 in the presence of HRTV and SFTSV NSs is due to an indirect interaction through the precipitation of STAT1-2 heterodimers or simply to a weak interaction. As it stands, the weak interaction or lack of direct interaction with STAT1 may play a role in the differential regulation of type I and type II IFN signaling by HRTV and SFTSV NSs. In canonical type I IFN signaling, STAT1-STAT2 heterodimers, in association with IRF-9, translocate to the nucleus and bind to ISREs. Under conditions of activation through type I or type II IFN, STAT1 can also form homodimers, which translocate to the nucleus to activate gamma-activated site (GAS) elements. Activation of GAS elements by STAT1 homodimers results in the production of proinflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and P40, which can cause severe disease (87). Our results indicate that HRTV and SFTSV NSs proteins are unable to inhibit type II IFN signaling (Fig. 6H), an observation which is supported by our data showing a weak interaction or a potential lack of direct interaction between these proteins and STAT1 as well as the inability of HRTV and SFTSV NSs proteins to block the nuclear translocation of STAT1. Furthermore, STAT3, which has also been implicated in modulating inflammatory responses (88), did not act as an interacting partner for UUKV, HRTV, or SFTSV NSs. Therefore, our results indicate that HRTV NSs can suppress type I IFN signaling through a direct interaction with STAT2 in a manner different from that seen in the sequestration of STAT2 into SFTSV NSs inclusion bodies. The weak interaction or lack of direct interaction of HRTV and SFTSV NSs with STAT1, and the lack of an interaction with STAT3, could act as an explanation for the strong cytokine-mediated inflammatory responses suggested to be responsible for disease progression in SFTSV mouse models as well as in patients diagnosed with SFTS (89, 90) and for the symptoms (identical to those seen in SFTS disease) that have been observed in HRTV patients (9, 10).

The first indication that the NSs protein of a Phlebovirus had an IFN antagonist role was the finding that, in comparison to virulent RVFV strain ZH548, RVFV strains bearing mutations in the NSs gene (MP12 and clone 13) induced IFN and were virulent in mice.
lacking the type I IFN receptor but not in wild-type mice (57). Thus, given that the sensitivity of RVFV to IFN is dictated by the capacity of the virus NSs protein to efficiently block the production of IFN following infection, we aimed to investigate the sensitivity to IFN of the tick-borne phleboviruses used in this report. Our results show that in IFN-competent A549 cells, the foci produced by UUKV were undetectable and the foci produced by SFTSV were small (Fig. 7A). However, when IFN signaling was impaired by addition of the JAK1/2 inhibitor ruxolitinib to the focus-forming assay overlay, UUKV foci could be detected and SFTSV formed significantly larger foci. These data suggest that the IFN response mounted as a result of virus infection results in an antiviral state in neighboring infected cells, which limits UUKV and SFTSV spread. Similarly, the inability of UUKV and SFTSV to reach similar peak titers during infections at low MOI and high MOI could be explained by the sensitivity of the viruses to induced IFN, limiting virus replication. Notably, some differences were observed in the ability of the viruses to interact with cells in an IFN-induced state. UUKV exhibited poor replication kinetics, presumably due to its inability to cope with the action of virus infection-induced IFN (Fig. 7B and E). These results are in line with our previous finding that UUKV NSs is a weak IFN antagonist (35), as the inability of UUKV to efficiently circumvent the IFN response may be a result of the weak IFN-antagonistic activity of its NSs protein. Comparatively, SFTSV exhibited faster replication kinetics throughout the time course despite inducing more IFN, suggesting that SFTSV is less sensitive to the action of IFN than UUKV (Fig. 7B, D, E, and G).

Other studies and the results described here suggested that the NSs protein of SFTSV is a potent IFN antagonist. However, a recent report showed that sera from SFTSV-infected patients show high concentrations of IFN-α compared to sera from healthy patients (59). Our results explain these observations and indicate that, despite encoding a potent IFN antagonist (Fig. 2 and 6), in the context of a virus infection, the amount of IFN induced during SFTSV infection is not completely overcome by the action of its viral IFN antagonist (Fig. 7). Perhaps SFTSV has evolved such a potent IFN antagonist to compensate for the generation of a large number of PAMPs during virus replication that result in the rapid induction of the IFN response—an interesting hypothesis and avenue for future studies. Interestingly, and in comparison to SFTSV, no significant difference was observed in HRTV focus size in A549 cells in comparisons of functional and nonfunctional IFN signaling responses (Fig. 7A). Low- and high-MOI HRTV infections resulted in similar peak titers, and little IFN was detected, suggesting that the virus can efficiently control IFN production following infection, which the data presented in the manuscript suggest is mediated by its NSs protein.

To conclude, our findings serve to expand our knowledge of the differential strategies evolved by phleboviruses to modulate host innate immune responses and highlight that, despite being poorly conserved in terms of amino acid sequence, the NSs proteins of phleboviruses retain their IFN antagonistic function.

MATERIALS AND METHODS

Cells and viruses. A549, HeLa, and Vero E6 cells (commonly used cell lines originally obtained from the European Collection of Authenticated Cell Cultures [ECACC] and previously described in references 64 and 91; Vero E6 cells were from Institut Pasteur) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS). HEK293T cells (ECACC) were grown in DMEM supplemented with 10%) FCS and 0.1 mM MEM nonessential amino acids (NEAA). BSR cells (a variant of BHK-21 cells; kindly provided by Karl-Claus Conzelmann) were grown in Glasgow’s MEM (GMEM) supplemented with 10% tryptose phosphate broth (TPB) and 10% FCS. Cells were maintained at 37°C with 5% CO2.

The wild-type UUKV strain used in this study was derived from the prototype S-23 strain and grown in BSR cells as previously described (35, 92). HRTV (isolated from patient 2 as described in reference 9) was a kind gift by R. Tesh (World Reference Centre for Emerging Viruses and Arboviruses, Galveston, TX). The SFTSV strain used was a plaque-purified cell culture-adapted stock strain called Hubei 29pp (HB29pp) provided by A. Lambert (CDC Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, Fort Collins, CO) (93). Working stocks of HRTV and SFTSV were generated in Vero E6 cells by infection at a low multiplicity of infection (MOI) and by harvesting the cell culture medium 7 days p.i. All experiments performed with HRTV or SFTSV were conducted under containment level 3 (CL-3) conditions approved by the UK Health & Safety Executive.
**Virus titration by plaque- or focus-forming assays.** Virus titers were determined by focus-forming assays in BSR cells for UUKV and by plaque assay in Vero E6 cells for HRTV and SFTSV. Briefly, confluent monolayers of cells were infected with serial dilutions of virus made in phosphate-buffered saline (PBS) containing 2% FCS and incubated for 1 h at 37°C, followed by the addition of a GMEM overlay supplemented with 2% FCS and 0.6% Avicel (FMC Biopolymer). The cells were incubated for 6 days before fixation and staining with crystal violet was performed to visualize HRTV and SFTSV plaques or using focus-forming assays for UUKV as described previously (35).

To investigate the effect of the JAK1/J2 inhibitor ruxolitinib (Selleck Chemicals) on focus formation, stocks were prepared at 10 mM in dimethyl sulfoxide (DMSO). Following virus infection of A549 cells, the Avicel overlay was supplemented with 0.4 μM ruxolitinib or the equivalent volume of the vehicle control DMSO. Foci were detected using anti-UUKV, anti-HRTV, and anti-SFTSV nucleocapsid antibodies (38, 93, 94).

**Indirect immunofluorescence staining.** For studies involving the subcellular localization of NS5 proteins, HEK293T or A549 cells were grown to subconfluence on glass coverslips (13-mm diameter) and infected at a high MOI (3 FFU or PFU/ml) with UUKV, HRTV, or SFTSV. At 24 h p.i., the cells were fixed with 4% formaldehyde–PBS. Following permeabilization with 0.1% Triton X-100–50 mM glycine–PBS, proteins were detected using rabbit anti-UUKV NSs (kindly provided by Anna Överby, Umeå University, Sweden), rabbit anti-HRTV NSs (described below), rabbit anti-SFTSV NSs (93), and secondary anti-rabbit Alexa Fluor 488 (Thermo Fisher). For indirect immunofluorescence staining of proteins following transfections, HEK293T or HeLa cells seeded in poly-L-lysine-coated or uncoated glass coverslips were transfected with the appropriate expression plasmids and fixed 24 h posttransfection. Cells were permeabilized and probed with primary antibodies mouse anti-V5 antibody (kindly provided by R. E. Randall, University of St. Andrews), rabbit anti-FLAG antibody (F7425; Sigma), rabbit anti-TBK1/NAK antibody (3013; Cell Signalling), rabbit anti-STAT1 p84/p91 antibody (sc-346; Santa Cruz Biotechnologies), and rabbit anti-STAT2 antibody (sc-476; Santa Cruz Biotechnologies) and secondary antibodies anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 568 (Thermo Fisher). The coverslips were mounted on slides using Fluoromount-G with DAPI (4′,6-diamino-2-phenylindole) (EBioscience). Fluorescently labeled proteins were visualized using a Zeiss LSM-710 confocal microscope.

**Expression plasmids and cloning.** Firefly luciferase reporter plasmids were used to investigate IFN-β promoter or ISRE promoter activation. p(125)luc and p(9–27)tkluc(-39)lucifer, have been described previously (95, 96). Control plasmid phRL-CMV coding for Renilla lucerase under the control of a cytomegalovirus (CMV) promoter was purchased from Promega. Untagged or C-terminally V5-tagged UUKV, HRTV, and SFTSV NSs sequences were cloned into the pCMV mammalian expression plasmid using restriction-free cloning. FLAG-tagged RIG-I N, MAVS, TBK1, IKKε, and IRF3-SD expression plasmids were kindly provided by Mirko Schmolke (University of Geneva) and have been described elsewhere (97, 98).

**Cloning of HRTV N and NS5 protein into a bacterial expression plasmid.** The coding region for HRTV N protein was amplified and cloned into a modified pDEST14 vector (Invitrogen) using Sacl and Xhol restriction sites, generating plasmid p14 HRTV N. Plasmid pHaloHRTV NSs131-299 that expresses a Halo fusion C-terminal domain (residues 131 to 299) of HRTV NSs protein was derived from pH6HTNiHsHaloTagT7-HRTV NSs, in which the full-length HRTV NSs was cloned into the modified pH6HTNiHsHaloTagT7 vector (Promega). Both p14HRTV N and pHaloHRTV NSs131-299 contain an N-terminal 6-His tag for purification of soluble HRTV N and NS5s.

**Expression and purification of HRTV N and NS5 protein for antibody production.** N and NS5 proteins were expressed in *Escherichia coli* BL21 Rosetta2 (Merck) and C43(DE3) (a gift from Huanting Liu, University of St. Andrews; originally from Lucigen Corporation) under conditions of IPTG (isopropyl-β-d-thiogalactopyranoside) induction at 18 to 20°C for 18 h. Recombinant N and NS5 proteins were purified with nickel-nitrilotriacetic acid (Ni-NTA) resin. Recombinant NS5s was further purified by gel filtration chromatography using a Superdex 200 10/300-G1 column. The purified N and NS5 proteins were confirmed by mass spectrometry and used for generating rabbit polyclonal antibodies (Eurogentec).

**Reporter assays.** ISRE reporter assays were carried out as previously described (85). IFN-β reporter assays were performed by cotransfection of NS5 proteins with expression plasmids encoding various stimuli of the IFN-β promoter (RIG-I N, MAVS, TBK1, IKKε, and IRF3-SD) as described previously (85). Briefly, subconfluent HEK293T cells in a 24-well plate were transfected using 1.5 μl TransIT LT-1 (Mirus Bio LLC) and plasmid DNA and were lysed 24 h later. The total amount of plasmid DNA was kept constant by addition of empty control plasmid. For ISRE reporter assays, transfected cells were stimulated with 500 U/ml of universal type I IFN (PBL Assay Science) and lysed 18 h post-IFN treatment. Firefly and Renilla luciferase activities in the reporter assays were measured using a dual-luciferase assay kit (Promega) according to the manufacturer’s instructions.

The IFN response was also measured through biological IFN assays, as described previously (35, 64, 99). For infection experiments, IFN-competent A549 cells were infected with wt UUKV, HRTV, or SFTSV at a low (0.1 FFU/cell) or high (3 FFU/cell) MOI. The cell culture medium was collected at the indicated time points and inactivated by UV light exposure (8 W; 254 nm at a distance of 2 cm for 4 min with occasional shaking). For transfection experiments, HEK293T cells induced by transfection of an expression plasmid encoding the N terminus of RIG-I were cotransfected with the different NS5s proteins, and the cell culture medium was harvested 24 h post-transfection. Twofold dilutions of cell culture medium or UV-inactivated medium were used to pretreat A549/BVDV-Npro cells for 24 h, followed by the addition of IFN-sensitive encephalomyocarditis virus (EMCV) (0.03 FFU/cell). Cell monolayers were stained with crystal violet 4 days later, and the relative IFN units (RIU) were calculated as 2^n, where N is the number of two-fold dilutions giving A549/BVDV-Npro cells protection.
Western anti-blotting. Western blotting was performed as previously described (35) using the following antibodies: anti-UUKV N monoclonal 8B11A3 (94), rabbit polyclonal UUKV NSs, HRTV and SFTSV polyclonal-anti-N and anti-NSs (93), mouse anti-VS, mouse anti-FLAG M2 (F1804; Sigma), mouse anti-α-tubulin (T5168; Sigma), mouse anti-β-actin (A5441; Sigma), anti-TBK1/NAK (3013; Cell Signalling), rabbit anti-phospho-TBK1/NAK (Ser172) (54835; Cell Signalling), rabbit anti-RIG-I (AT111; Enzo Life Sciences), rabbit anti-IRF-3 (FL425; Sigma), rabbit anti-IRF-3 (phospho-S386) (76493; Abcam, Inc.), rabbit anti-STAT1 p84/p91 (sc-346; Santa Cruz Biotechnologies), rabbit anti-STAT2 (sc-476; Santa Cruz Biotechnologies), rabbit antistat 1 Tyr701P (9167; Cell Signalling), rabbit antistat 1 Ser727P (9177; Cell Signalling), rabbit antistat 2 Tyr690P (4441; Cell Signalling), and rabbit anti-STAT3 (sc-482; Santa Cruz Biotechnologies).

For detection of dimerized IRF-3, cells were lysed in a nonreducing lysis buffer (50 mM Tris HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40) supplemented with protease and phosphatase inhibitors, separated on a nonreducing gel, and transferred to a Hybond ECL nitrocellulose membrane (GE Healthcare Life Sciences) prior to blocking in Tris-buffered saline (TBS)/0.1% bovine serum albumin (BSA; Sigma) and probing with IRF-3 antibody. Upon incubation with horseradish peroxidase (HRP)-coupled secondary antibody, proteins were detected using Clarity ECL blotting substrate (Bio-Rad) and visualized with a Bio-Rad ChemiDoc imager.

Coimmunoprecipitation studies. Coimmunoprecipitation (co-IP) was carried out using either transfected or infected cell monolayers. For transfections, subconfluent HEK293T cells were cotransfected with expression plasmids encoding V5-tagged NSs proteins and plasmids encoding FLAG-tagged RIG-I N, MAVS, TBK1, and IKKε or IRF3-3D. For co-IP of NSs from virus-infected cells, HEK293T or A549 cells were infected at an MOI of 20 or 5 with UUKV or HRTV, respectively. At the indicated time points, cells were lysed in co-IP buffer (50 mM Tris HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 10% gycrol, 1% NP-40, supplemented with a cocktail of cOmplete protease inhibitors [Roche]) and incubated by rotation at 4°C for 30 min. UUKV-infected cells were lysed in a different co-IP buffer (25 mM HEPES [pH 7.5], 150 mM NaCl, 50 mM MgCl2, 1% Triton X-100, supplemented with a cocktail of complete protease inhibitors [Roche]). Cell lysates were clarified by centrifugation at 12,000 rpm for 20 min at 4°C. At this stage, the whole-cell lysate (WCL) fraction was taken.

For co-IP of FLAG-tagged proteins, anti-FLAG M2 magnetic beads (Sigma) were used for incubation with clarified cell lysates at 4°C for 4 h. For co-IP of UUKV NSs or HRTV NSs, clarified cell lysates were incubated overnight at 4°C with rabbit polyclonal anti-UUKV or anti-HRTV NSs antibody, respectively, followed by the addition of protein G magnetic Dynabeads (Thermo Fisher). For co-IP of V5-tagged proteins, clarified cell lysates were incubated overnight at 4°C with mouse anti-VS antibody, followed by the addition of protein G magnetic Dynabeads (Thermo Fisher). All beads were used according to the manufacturer’s instructions. Following incubation of the cell lysates with the beads for 1.5 h at 4°C, the beads were washed five times with co-IP buffer and two times with PBS before elution of antibody complexes was performed. Elution of proteins was carried out by the addition of reducing Laemmli buffer and boiling at 95°C for 10 min. Eluates were analyzed by Western blotting, using a VeriBlot IP secondary antibody (ab131366; Abcam, Inc.).

Quantitative RT-PCR. Total cellular RNA was extracted with RNAiso Plus (TaKaRa). Random hexamer primers were used to transcribe cDNA using a Transcriptor First Strand cDNA synthesis kit (Roche), and SYBR Premix Ex Taq II mix (TaKaRa) was used for real-time PCR (RT-PCR). Reactions were carried out in triplicate on an ABI StepOnePlus system (Applied Biosystems). The relative levels of expression of mRNA were calculated using threshold cycle (ΔΔCt) analysis, and the values were normalized to the relative mRNA expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The following primers were used:

- 5′-GCTGTTGTCATACTTCTCATGG-3′ for CXCL10,
- 5′-GTTGGGAAGTGTAAGCGAT-3′ for IL-1β,
- 5′-CCCTCCAAAAT-3′ for IFN-β,
- 5′-ATCCCCACATGACTTCCTCTT-3′ for IRF1, and
- 5′-GGAGCGAGATCCCTCCAAAAT-3′ and 5′-GGCTTTGTGCACTTCTCATGG-3′ for GAPDH.

Statistical analysis. All data were analyzed using Prism 5 software (GraphPad) and are presented as means ± standard deviations (SD) or standard errors of the means (SEM). Statistical significance for the comparison of means between groups was determined by one-way or two-way analysis of variance (ANOVA) followed by post hoc tests. P values of ≤0.05 were considered significant (***, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/mSphere.00234-17.

FIG S1, TIF file, 10 MB.
FIG S2, TIF file, 3.7 MB.
FIG S3, TIF file, 4.8 MB.
FIG S4, TIF file, 12.2 MB.

ACKNOWLEDGMENTS

We thank R. E. Randall (University of St. Andrews) and A. Kohl (University of Glasgow) for helpful advice and discussion and M. Schmolke and B. Hale for providing us with IFN-related plasmids. We thank A. Kohl, I. C. van Knippenberg, and X. Shi (University of Glasgow) for critical reading of the manuscript.

Work at the University of Glasgow was supported by a Wellcome Trust Senior...
Kong was supported by grants from the Hong Kong Research Grants Council (N-HKU Investigator award (099220/Z/12/Z) awarded to R.M.E. Work at the University of Hong

Rezelj et al.

Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses. J Virol. 2006. 80:5059–5064. https://doi.org/10.1128/JVI.80.9.5059-5064.2006

Evasion of antiviral immunity through sequestering of TBK1/IKKepsilon/IRF3 into viral inclusion bodies. J Virol. 2006. 80:3067–3076. https://doi.org/10.1128/JVI.80.9.3067-3076.2006

Small rodents. Acta Virol 14:163–166.

that contributes to viral pathogenesis. Proc Natl Acad Sci U S A 98:664–669. https://doi.org/10.1073/pnas.98.2.664

Saffo T, Tateo S, Ghiara S, Konno M, Taira K. 2015. Viral suppression of innate immunity via spatial sequestration of TBK1/IKKepsilon. Mol Cell Biol. 6:324–337.

Kadowaki T, Doi K, Okuda M, Umeki K, Saito T, Sakaguchi S, Satoh A, Hosokawa T, Kawabe Y, Kurihara S, Izumikawa H, Sato T, Fukushima K, Nakajima K, Yoshikawa T, Tani H, Fukushi S, Fukuda A, Ogata M, Shimojima M, Nakajima N, Nagata N, Kato K, Fukumoto H, Saito T, Hasegawa H, Yamagishi T, Dishi K, Kurane I, Morikawa S, Satojo M. 2014. The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 209:891–827. https://doi.org/10.1093/infdis/jit063.

Muenchelbachs A, Fata CR, Lambert AJ, Padlock CD, Velez JO, Blu M, Staples JE, Karlekar MB, Bhimagar J, Nasell RS, Zaki SR. 2015. Malsoor virus, a novel bunyavirus found in the Amblyomma americanum and invertebrate viruses. J Virol 88:11480–11492. https://doi.org/10.1128/JVI.03510-15

HAM174, and Ixodes scapularis ticks reveals novel highly divergent vertebrate and invertebrate viruses. J Virol 88:11480–11492. https://doi.org/10.1128/JVI.03510-15

AnewPhlebovirusassociatedwithseverefebrileillnessinMissouri.NEnglJMed367:834–841.

that contributes to viral pathogenesis. Proc Natl Acad Sci U S A 98:664–669. https://doi.org/10.1073/pnas.98.2.664

and Ixodes scapularis ticks reveals novel highly divergent vertebrate and invertebrate viruses. J Virol 88:11480–11492. https://doi.org/10.1128/JVI.03510-15

Muenchelbachs A, Fata CR, Lambert AJ, Padlock CD, Velez JO, Blu M, Staples JE, Karlekar MB, Bhimagar J, Nasell RS, Zaki SR. 2015. Malsoor virus, a novel bunyavirus found in the Amblyomma americanum and invertebrate viruses. J Virol 88:11480–11492. https://doi.org/10.1128/JVI.03510-15

Batt {{Cite book | last1 = McAllister | first1 = J | last2 = Mitchell | first2 = IR | last3 = St George | first3 = TD | last4 = Cybinski | first4 = DH | last5 = Davis | first5 = SS | year = 2011 | title = Hunter Island group phlebovirus in ticks. Australia. Emerg Infect Dis | volume = 17 | issue = 7 | pages = 1143–1003 | date = | doi = 10.3201/eid1707.110727

Meningitis, USA. Emerg Infect Dis 19:1892–1894. https://doi.org/10.3201/eid1911.1307092.

Y. 2015. Hunter Island group phlebovirus in ticks. Australia. Emerg Infect Dis 17:1143–1003.

Meningitis, USA. Emerg Infect Dis 19:1892–1894. https://doi.org/10.3201/eid1911.1307092.

Y. 2015. Hunter Island group phlebovirus in ticks. Australia. Emerg Infect Dis 17:1143–1003.

Meningitis, USA. Emerg Infect Dis 19:1892–1894. https://doi.org/10.3201/eid1911.1307092.

Y. 2015. Hunter Island group phlebovirus in ticks. Australia. Emerg Infect Dis 17:1143–1003.

Meningitis, USA. Emerg Infect Dis 19:1892–1894. https://doi.org/10.3201/eid1911.1307092.
syndrome virus through inhibition of STAT1 phosphorylation and activation. J Gen Virol 96:3204–3211. https://doi.org/10.1099/0.00280.

34. Ning YJ, Feng K, Min YQ, Cao WC, Wang M, Deng F, Hu Z, Wang H. 2015. Disruption of type I interferon signaling by the nonstructural protein of severe fever with thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies. J Virol 89:4227–4236. https://doi.org/10.1128/JVI.00154-15.

35. Rezej V, Overby AK, Elliott RM. 2015. Generation of mutant Uukuniemi viruses lacking the nonstructural protein NSs by reverse genetics indicates that NSs is a weak interferon antagonist. J Virol 89:4849–4856. https://doi.org/10.1128/JVI.03511-14.

36. Elliott RM. 2014. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol 12:673–685. https://doi.org/10.1038/nrmicro3332.

37. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, Lopez R. 2013. Analysis Tool Web services from the EMBL-EBI. Nucleic Acids Res 41:w597–w600. https://doi.org/10.1093/nar/gkt376.

38. McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, Lopez R. 2013. Interferon and cytokine response signals mediate interactions between dimeric STAT3, and importin alpha 1. J Biol Chem 287:30072–30078. https://doi.org/10.1074/jbc.M112867200.

39. Onoguchi K, Onomoto K, Takamatsu S, Jogi M, Takemura A, Morimoto A. 2011. The IRF-3 activation of a transcription factor complex containing IRF-3 and CBP/p300 depends on the similarity to other bunyavirus NSs proteins. Virol J 8:243–245.

40. Panne D, McWhirter SM, Maniatis T, Harrison SC. 2007. Interferon and cytokine response signals mediate interactions between dimeric STAT3, and importin alpha 1. J Biol Chem 282:22816–22822. https://doi.org/10.1074/jbc.M703019200.

41. Lin R, Heybrock C, Sitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 18:2986–2996. https://doi.org/10.1089/mcb.18.5.2986.

42. Pegg EA, McWhirter SM, Failla KL, Rowc DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. 2003. IFK epsilon and IFI-1 are essential components of the IFR3 signaling pathway. Nat Immunol 4:491–496. https://doi.org/10.1038/ini921.

43. Kawai T, Takeda K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and MDA5-mediated type I interferon induction. Nat Immunol 6:981–987. https://doi.org/10.1038/ni1243.

44. Komilina E, Lunardi T, McCarthy AA, Loubier J, Brunel J, Grigorov B, Gerlier D, Cursac S. 2011. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 147: 423–435. https://doi.org/10.1016/j.cell.2011.09.039.

45. Onoguchi K, Onomoto K, Takamatsu S, Jogi M, Takemura A, Morimoto S, Iwakuni N, Namiki H, Yoneyama M, Fujita T. 2005. Inhibition of type I interferon signaling by the nonstructural protein NSs of Uukuniemi virus with the 40S ribosomal subunit. J Virol 66:4233–4241.

46. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. 2001. IFN-gamma T cell receptor-dependent IFN-alpha/beta activation of the type I interferon pathway: Notch activation of a transcription factor complex containing IRF-3 and CBP/p300. J Biol Chem 276:42413–42419. https://doi.org/10.1074/jbc.M100815200.

47. McIver EG, Cohen P. 2011. Novel cross-talk within the IKK family of kinases regulates innate immunity. Biochem J 434:93–104. https://doi.org/10.1042/BJ20101701.

48. McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, Lopez R. 2013. Analysis Tool Web services from the EMBL-EBI. Nucleic Acids Res 41:w597–w600. https://doi.org/10.1093/nar/gkt376.

49. McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, Lopez R. 2013. Analysis Tool Web services from the EMBL-EBI. Nucleic Acids Res 41:w597–w600. https://doi.org/10.1093/nar/gkt376.

50. Ho HH, Ivashkiv LB. 2006. Role of STAT3 in type I interferon responses. J Biol Chem 281:1371–1377. https://doi.org/10.1074/jbc.M110000200.

51. Rymann KD, Klmistra WB, Nguyen KB, Biron CA, Johnston RE. 2000. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 74:3366–3378. https://doi.org/10.1128/JVI.74.3.3366-3378.2000.

52. Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T, Yoshikai Y. 2013. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res 99:230–237. https://doi.org/10.1016/j.antiviral.2013.05.007.

53. Ly HJ, Ikegami T. 2016. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virol J 13:118. https://doi.org/10.1186/s12985-016-0573-8.

54. Brenner B, Welch SR, Elliott RM. 2014. The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging. PLoS Pathog 10:e1003922. https://doi.org/10.1371/journal.ppat.1003922.

55. Cyr N, de la Fuente C, Lecoq L, Guendel I, Chabot PR, Kehn-Hall K, McIver EG, Cohen P. 2011. A OmegaXav motif in the Rift Valley fever virus NSs protein is essential for degradation p62, forming nuclear filaments and virulence. Proc Natl Acad Sci U S A 111:2601–2623. https://doi.org/10.1073/pnas.1109368112.

56. Brennan B, Welch SR, Elliott RM. 2014. The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging. PLoS Pathog 10:e1003922. https://doi.org/10.1371/journal.ppat.1003922.

57. Mimica-Dukic V, Simeone O, Manocha GR, Zernoeff J, Bonneau E, Bouloy M. 2013. Dicer-2- and piwi-mediated RNA interference in Rift Valley fever virus-infected mosquito cells. J Virol 87:1631–1648. https://doi.org/10.1128/JVI.00755-12.

58. Struthers JK, Swanepoel R. 1982. Identification of a major nonstructural protein in the nucleocapsid of Rift Valley fever virus-infected mosquito cells. J Virol 87:1631–1648. https://doi.org/10.1128/JVI.00755-12.
fever virus recruits the F-box protein FBXO3 to degrade subunit p62 of general transcription factor TFIIH. J Virol 88:3464–3473. https://doi.org/10.1128/JVI.02914-13.

71. Le May N, Mansuroglu Z, Léger P, Josse T, Blot G, Billecocq A, Flick R, Jacob Y, Bonnefoy E, Bouloy M. 2008. A Sapo30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 4:e13. https://doi.org/10.1371/journal.ppat.0004013.

72. Kainulainen M, Lau S, Samuel CE, Hornung V, Weber F. 2016. NSs virulence factor of Rift Valley fever virus engages the F-box proteins FBXW11 and beta-TRCP1 to degrade the antiviral protein kinase PKR. J Virol 90:6140–6147. https://doi.org/10.1128/JVI.00016-16.

73. Carlton-Smith C, Elliott RM. 2012. Viperine, MTAP44, and protein kinase R contribute to the interferon-induced inhibition of Bunyamwera Orthobunyavirus replication. J Virol 86:11548–11557. https://doi.org/10.1128/JVI.01773-12.

74. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, Unger H, Weber F. 2009. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 83:4365–4373. https://doi.org/10.1128/JVI.02148-08.

75. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. 2009. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5:e1000287. https://doi.org/10.1371/journal.ppat.1000287.

76. Kalveram B, Ihoradova O, Indran SV, Lokugamage N, Head JA, Ikegami T. 2013. Rift Valley fever virus NSs proteins host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. Virology 435:415–424. https://doi.org/10.1016/j.virol.2012.09.031.

77. Kalveram B, Ikegami T. 2013. Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase. J Virol 87:3710–3718. https://doi.org/10.1128/JVI.02506-12.

78. Gori Savelli G, Weber F, Terresi C, Habjan M, Martorelli B, Cusi MG. 2011. Toscana virus induces interferon although its NSs protein reveals antagonistic activity. J Gen Virol 92:71–79. https://doi.org/10.1099/vir.0.025999-0.

79. Gori-Savelli G, Valentini M, Cusi MG. 2013. Toscana virus NSs protein inhibits the induction of type I interferon by interacting with RIG-I. J Virol 87:6660–6667. https://doi.org/10.1128/JVI.03129-12.

80. Ihoradova OA, Indran SV, Kalveram B, Lokugamage N, Head JA, Gong B, Tigabu B, Jeuel LC, Freiberg AN, Ikegami T. 2013. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus. PLoS Negl Trop Dis 7:e2181. https://doi.org/10.1371/journal.pntd.0002181.

81. Wu X, Qi X, Liang M, Li C, Cardona CJ, Li D, Xing Z. 2014. Roles of viroplasm-like structures formed by nonstructural protein NSs in infection with severe fever with thrombocytopenia syndrome virus. FASEB J 28:2504–2516. https://doi.org/10.1096/fj.13-243857.

82. Thomas NJ, Hunter DB, Atkinson CT. 2007. Infectious diseases of wild birds, p 37. In Thomas NJ, Hunter DB, Atkinson CT (ed), Infectious diseases of wild birds. Wiley-Blackwell, Hoboken, NJ.

83. Saikku P. 1974. Passerine birds in the ecology of Uukuniemi virus. Med Biol 52:98–103.

84. Varga ZT, Grant A, Manicassamy B,Palese P. 2012. Influenza virus protein P81-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential. J Virol 86: 8359–8366. https://doi.org/10.1128/JVI.01122-12.

85. Varga ZT, Ramos I, Haidar R, Schmolke M, García-Sastre A, Fernandez-Sesma A, Palese P. 2011. The influenza virus protein P81-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 7:e1002067. https://doi.org/10.1371/journal.ppat.1002067.

86. Koshiba T, Yasukawa K, Yanagi Y, Kawabata S. 2011. Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling. Sci Signal 4ra7. https://doi.org/10.1126/scisignal.2001147.